RxDoctor Payments DataLook up a doctor →

Amy Chien, MD

Medical Oncology · San Francisco, CANPI 1922242932

Payments from drug & device makers

$10,459,178in general payments, 2019–2025

Across 390 payments — averaging $26,818 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$4.2M
  • Amgen$2.2M
  • Merck$1.3M
  • Puma Biotechnology, Inc.$824K
  • Regeneron$613K
  • Seagen Inc.$547K
  • plus $707K from 9 others
$330in research payments, 2019–2025

Across 1 payment — averaging $330.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$330

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer203$4,230,703
Amgen11$2,247,022
Merck19$1,290,294
Puma Biotechnology, Inc.13$824,130
Regeneron12$613,193
Seagen Inc.97$547,239
AstraZeneca6$340,377
Jazz Pharmaceuticals Inc.7$315,183
Astrazeneca UK Limited1$26,612
Genentech USA, Inc.8$12,155
Eli Lilly1$5,361
Sanofi1$3,090
Novartis2$1,888
Gilead8$1,763
GE HealthCare1$169

How this compares

$10,459,178 in reported general payments places this provider in the 95th percentile of 379 medical oncology providers in California.

See all medical oncology providers in California

Medicare billing

Part B allowed, 2024
$103,343
Medicare patients
135
Services billed
1,631

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →